Navigation Links
NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance
Date:3/31/2009

SALT LAKE CITY, March 31 /PRNewswire-FirstCall/ -- Dynatronics Corporation (Nasdaq: DYNT) today announced that NASDAQ has filed a third grace period extension with the SEC, giving the company until approximately September 27, 2009, to comply with NASDAQ's $1 per share minimum bid rule.

"We are pleased that NASDAQ has again extended the timeframe for compliance," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "This will allow us time to announce our year-end results, which are expected to show significant improvement over the prior year."

Dynatronics recently reported a profit for the quarter ended December 31, 2008, showing substantially improved results for that period. The company also announced it had retained Vici Capital to assist in seeking ways to improve revenues and minimize expenses. Partly as a result of that process, the company has taken steps to reduce annual expenses by approximately $1,000,000. Additional savings are expected to be achieved in subsequent months from this effort.

"In the quarter ending June 30, 2009, we plan to introduce a new, high-margin product to the physical medicine market," Cullimore added. "The combination of new products, reduced expenses and improved revenues is expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations for future events. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements in this press release include the statements concerning anticipated improvements for the quarter ending June 30, 2009, the anticipated impact of the introduction of a new product in the quarter ending June 30, 2009, the expectation that changes implemented with the assistance of Vici Capital will reduce operating expenses by approximately $1,000,000, the expectation that additional savings are expected to be achieved in the coming months, and the statement that these developments are expected to lead to significantly improved operating results and generate sustainable earnings improvements for the company. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq
2. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
3. NASDAQ Panel Grants Extension to DATATRAK for Continued Listing on the NASDAQ Capital Market
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination
6. The LCA-Vision Full Value Committee Urges LCA-Vision (NASDAQ: LCAV) Stockholders to Reject the Status Quo
7. Pharmacyclics Receives Nasdaq Notification
8. Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Opening Bell
9. Cell Therapeutics to Resume Trading on MTA and NASDAQ
10. The LCA-Vision Full Value Committee Commences Consent Solicitation to Elect New Board of Directors at LCA-Vision (Nasdaq: LCAV) and Sends Letter to Stockholders
11. EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
Breaking Medicine News(10 mins):
(Date:9/22/2017)... 2017 AVACEN Medical (AVACEN) announced that its ... helping those with the widespread pain associated with fibromyalgia ... in Essex, England commented, "I ... experiencing no sleep at all, tremendous pain, with every ... recommend [the AVACEN 100] enough, how this has and ...
(Date:9/18/2017)... , Sept. 18, 2017  PMD Healthcare of ... Pharmacy of Kalamazoo, Mich. , have ... service that expedites and streamlines patient and provider access ... 2.0, and wellness management services.  ... used to measure lung function for a variety of ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
Breaking Medicine Technology: